Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/10/21 | $45,000,000 | Series B |
Blue Stem Capital Longitude Capital Medicxi RA Capital Management SC Master Fund Visionary Ventures Fund | undisclosed |
